|
Impact of decipher test on adjuvant and salvage treatments received following radical prostatectomy. |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
|
|
|
Travel, Accommodations, Expenses - GenomeDx |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Swan Valley Medical |
Honoraria - Astellas Pharma; Bayer; Dendreon; Janssen; Medivation/Astellas |
Consulting or Advisory Role - Astellas Pharma; Bayer; Dendreon; Janssen; Medivation/Astellas |
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Dendreon; Janssen; Medivation |
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon (Inst); Janssen (Inst); Medivation/Astellas (Inst); Spectrum Pharmaceuticals |
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; dendreon; Janssen; Medivation/Astellas; Spectrum Pharmaceuticals |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - MDxHealth; Myriad Genetics |
Research Funding - Argos Therapeutics (Inst); GenomeDx (Inst); Myriad Genetics (Inst) |
Travel, Accommodations, Expenses - MDxHealth |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - GenomeDx |
|
|
No Relationships to Disclose |
|
|
|
|
Stock and Other Ownership Interests - GenomeDx |
Patents, Royalties, Other Intellectual Property - CANCER DIAGNOSTICS USING BIOMARKERS 20140066323 |
Travel, Accommodations, Expenses - GenomeDx |
|
|
Consulting or Advisory Role - Augmenix; BioCancell; MDxhealth; pacific edge; Photocure; Physical Optics Corporation; SonaCare Medical |
Research Funding - Abbott Molecular (Inst); Augmenix; Cepheid; Cepheid (Inst); Danone; GenomeDx (Inst); MDxHealth (Inst); pacific edge; pacific edge (Inst) |
|
|
Consulting or Advisory Role - Astellas Pharma |
Research Funding - GenomeDx (Inst); Genomic Health (Inst); MDxHealth (Inst) |